Related Experiment Video
Updated: Nov 11, 2025

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
Published on: June 16, 2011
Lower threshold to NFκB activity sensitizes murine β-cells to streptozotocin
Clyde J Wright1, Sarah McKenna1, Robyn De Dios1
1Section of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Abstract:
The β-cell response to injury may be as critical for the development of diabetes as the specific insult. In the current study, we used streptozotocin (STZ) to injure the β-cell in order to study the response with a focus on NFκB. MIN6 cells were exposed to STZ (0.5-8 mM, 0-24h) ±TNFα (100 ng/mL) and ±IκBβ siRNA to lower the threshold to NFκB activation. Cell viability was determined by trypan blue exclusion. NFκB activation was determined by the expression of the target genes Nos2 and Cxcl10, localization of the NFκB proteins p65 and p50, and expression and localization of the NFκB inhibitors, IκBβ and IκBα. There was no NFκB activation in MIN6 cell exposed to STZ (2 mM) alone. However, knocking down IκBβ expression using siRNA resulted in STZ-induced expression of NFκB target genes and increased cell death, while co-incubation with STZ and TNFα enhanced cell death compared to either exposure alone. Adult male IκBβ-/- and WT mice were exposed to STZ and monitored for diabetes. The IκBβ-/- mice developed hyperglycemia and diabetes more frequently than controls following STZ exposure. Based on these results we conclude that STZ exposure alone does not induce NFκB activity. However, lowering the threshold to NFκB activation by co-incubation with TNFα or lowering IκBβ levels by siRNA sensitizes the NFκB response to STZ and results in a higher likelihood of developing diabetes in vivo. Therefore, increasing the threshold to NFκB activation through stabilizing NFκB inhibitory proteins may prevent β-cell injury and the development of diabetes.
Insights
Streptozotocin (STZ) alone does not activate NFκB in beta cells. However, reducing IκBβ or adding TNFα sensitizes cells to STZ, increasing diabetes risk. Stabilizing NFκB inhibitors may prevent beta-cell injury.
Area of Science:
- Endocrinology
- Immunology
- Molecular Biology
Background:
- The role of beta-cell response to injury in diabetes development is crucial.
- Nuclear Factor kappa B (NFκB) signaling is implicated in cellular stress responses.
Purpose of the Study:
- To investigate the role of NFκB activation in streptozotocin (STZ)-induced beta-cell injury.
- To determine how modulating IκBβ levels affects STZ-induced NFκB activation and beta-cell death.
Main Methods:
- MIN6 cells and IκBβ knockout (IκBβ-/-) mice were treated with STZ, TNFα, and/or IκBβ siRNA.
- NFκB activation was assessed by gene expression (Nos2, Cxcl10), protein localization (p65, p50), and inhibitor levels (IκBβ, IκBα).
- Cell viability was measured using trypan blue exclusion, and diabetes onset in mice was monitored.
Main Results:
- STZ alone (2 mM) did not induce NFκB activation in MIN6 cells.
- Knocking down IκBβ with siRNA or co-incubation with TNFα sensitized MIN6 cells to STZ, leading to increased NFκB target gene expression and cell death.
- IκBβ-/- mice exhibited a higher incidence of STZ-induced hyperglycemia and diabetes compared to wild-type controls.
Conclusions:
- STZ-induced beta-cell injury and diabetes development are dependent on the sensitization of the NFκB pathway.
- Lowering the threshold for NFκB activation enhances STZ's diabetogenic effects.
- Stabilizing NFκB inhibitory proteins may offer a therapeutic strategy to prevent beta-cell injury and diabetes.

